- Patients
- Clinical Research
- Clinical trials
- RADIANT
2024-06-20T09:24:22.012Z
RADIANT
RADIANT
Prostate cancer
A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH.
A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH.
Trial overview
Clinical Area
Theranostics
Disease / Condition
Prostate Cancer
Study Phase
III
Trial Identifiers
GenesisCare Location(s)
GenesisCare North Shore
Principal Investigator(s)
Laurence Krieger